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a b s t r a c t
Cyclophosphamide’s lack of hematopoietic stem cell toxicity and its unique effects on the immune system
have prompted several investigators to explore its potential for the prevention of graft-versus-host disease
(GVHD). In haploidentical hematopoietic stem cell transplants, post-transplant cyclophosphamide together
with standard prophylaxis reduces the incidence of GVHD to acceptable rates without the need for T cell
depletion. In matched related and unrelated donor settings, cyclophosphamide alone has produced
encouraging results. In particular, the low incidence of chronic GVHD is noteworthy. Here, we present a
review of the current understanding of the mechanism of action of post-transplant cyclophosphamide and
summarize the clinical data on its use for the prevention of GVHD.
Ó 2015 American Society for Blood and Marrow Transplantation.

INTRODUCTION
Although considerable advances have been made in HLA
matching and donor selection, graft-versus-host disease
(GVHD) remains a major impediment to the development
and widespread applicability of allogeneic blood and marrow
transplantation [1-3]. Despite the routine use of prophylactic
therapies, acute GVHD complicates 40% to 50% of transplants,
whereas chronic GVHD is encountered in 10% to 80% of cases
[1-3]. The detrimental effect of current prophylactic regimens on immune reconstitution and the potential to abolish
graft-versus-disease (GVD) effect have provided additional
impetus to develop alternative regimens.
In 1963, based on personal work and that of others,
Berenbaum [4] reported that skin allografts in mice have
better survival after the administration of a single dose of
cyclophosphamide 1 to 3 days after grafting. Subsequent
animal experiments and clinical trials enhanced our understanding of the immune modulatory effects of cyclophosphamide and established a platform for innovation and
progress in the ﬁeld of transplantation. Here, we review the
data on the use of post-transplant high-dose cyclophosphamide for the prevention of GVHD.
Financial disclosure: See Acknowledgments on page 610.
* Correspondence and reprint requests: Ahmad Samer Al-Homsi, Blood
and Marrow Transplantation, Spectrum Health, MC269, 145 Michigan Street
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RATIONALE AND MECHANISM OF ACTION
Cyclophosphamide is an alkylating agent of the nitrogen
mustard category. It has been in use for many years and has an
excellent toxicity proﬁle [5]. Cyclophosphamide is oxidatively
metabolized by the hepatic cytochrome P450 into 2 powerful
metabolites, phosphoramide mustard and acrolein, and prevents cell division by crosslinking DNA strands. Although the
alkylating effect of the active metabolites occurs throughout
the cell cycle, it is most pronounced during the G1 and S
phases of cell division [6]. Rapidly proliferating cells subjected
to DNA crosslinking are more susceptible to cyclophosphamide because of their reduced ability to replicate damaged
DNA. Conversely, hematopoietic stem cells that are rich in
aldehyde dehydrogenase, the enzyme required for the
conversion of phosphoramide mustard into the inactive
metabolite carboxycyclophosphamide, are resistant to cyclophosphamide. Consequently, cyclophosphamide can be
administered after allogeneic hematopoietic cell transplant
without impairing engraftment [7].
A fundamental difference of the effect of cyclophosphamide on T cells in contrast to other immunosuppressive
agents is its ability to induce apoptosis. Comparing the
effects of different drugs on human peripheral blood T cells,
cytotoxic cell lines, and Jurkat T cells, Strauss et al. [8] found
that only cyclophosphamide (and methotrexate) triggered
cell death. All other drugs, including steroids, calcineurin
inhibitors, sirolimus, and mycophenolate mofetil (MMF)
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inhibited T cells without causing apoptosis. In addition,
cyclophosphamide up-regulated Fas (CD95) expression,
triggering activation-induced cell death within 6 days of
activation. None of the other drugs affected CD95 expression.
Early animal experiments identiﬁed cyclophosphamide as
the most effective drug to suppress antibody production in
response to bacterial vaccines [9]. In addition, unlike other
antimitotics, cyclophosphamide did not need to be used at
low doses over prolonged periods of time [4,9]. In organ
transplantation, pivotal experiments showed that cyclophosphamide administered intraperitoneally in single high
dose early after skin allografts in mice was sufﬁcient to delay
graft rejection across MHC mismatches. The timing of
cyclophosphamide administration was critical [4,10].
Although administration of cyclophosphamide to mice
before or simultaneously with allogeneic stimuli suppressed
antibody production, tolerance was not induced. The
maximal effect in improving graft survival was observed
when cyclophosphamide was given between grafting and
day 4 afterward [4,10]. Furthermore, although cyclophosphamide only delayed graft rejection in MCH mismatches, it
induced deﬁnitive tolerance across minor histocompatibility
mismatches [11,12].
Based on earlier experiments performed by Nirmul et al.
[11,12], Mayumi et al. [13] established a “cells-followed-bycyclophosphamide” scheme in which administration of
allogeneic spleen cells followed by cyclophosphamide
administration 2 days thereafter induced tolerance to allografts in different mouse models. Several studies have
examined the mechanism of action of cyclophosphamide.
Vb6-bearing T cells directed to minor lymphocyte stimulating-1a (Mls-1a) were examined in a skin allograft experiment in which BALB/c mouse recipient (Mls-1b) were
rendered tolerant to DBA/2 mouse donor (Mls-1a) with
donor spleen cells and cyclophosphamide [14]. In the early
phase, the donor-reactive proliferative CD4þ-Vb6 T cells in
the lymph nodes were destroyed (clonal destruction),
whereas the resting CD8þ-Vb6þ T cells were spared.
Furthermore, neither immature CD4þ-Vb6 nor immature
CD8þ-Vb6 present in the thymus on day 14 were detectable
by day 35 (clonal deletion). In contrast to clonal destruction,
clonal deletion was long-lasting. These ﬁndings were supported by similar experiments based on different models
[15-17]. In one similar study, the complete disappearance of
CD4þ cells in the periphery was delayed until thymus
depletion occurred [18].
In hematopoietic stem cell transplantation, the same 2
mechanisms of action of cyclophosphamide were conﬁrmed
to prevent GVHD by affecting host-reactive cells. When AKR/
J-derived Thy-1.1 cells expressing Vb3 directed against Mls-2a
were examined in a model using a CH3/He mouse recipient
(H-2k, Mls-1b, Mls-2a) and AKR/J mouse donor (H-2k, Mls-1a,
Mls-2b), cyclophosphamide similarly induced early clonal
destruction of donor cells followed by clonal deletion of hostreactive cells [19]. These results were supported by the
ﬁndings by Huyan et al. [20], who examined the effect of
intraperitoneal administration of cyclophosphamide on peripheral blood lymphocyte counts in mice. Although 50 mg/
kg produced no signiﬁcant effect, higher doses induced a
dose-dependent decrease in CD4þ cells. The decrease began
on day þ1 and reached nadir on day þ4. After a transient
rebound, cell numbers decreased again after day þ10. The
same pattern was observed for B lymphocytes. In contrast,
CD8þ cells increased on day 4 [20]. Conceivably, the early
decrease in CD4þ but not CD8þ counts was due to clonal
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destruction, whereas the later decrease in CD4þ was secondary to thymocyte depletion.
Nirmual et al. [11,12] observed that timely administration
of cyclophosphamide prevented sensitization of mice
receiving large dose of donor spleen cells to skin allografts
and prolonged the survival of the grafts. They postulated that
cyclophosphamide acted on proliferating cells triggered into
cycling after contact with antigen. Their hypothesis was
recently conﬁrmed by Ross et al. [21]. In a GVHD mouse
model, donor cells were labeled with proliferation dyes and
traced in syngeneic and allogeneic transplantation experiments. Mice received increasing doses of cyclophosphamide
3 to 4 days after transplantation. In the syngeneic model,
lymphopenia-induced T cell proliferation was slow, sparing a
large fraction of cells; the nondeleted cells retained functionality. In the allogeneic model, 22 mg/kg cyclophosphamide failed to prevent GVHD when antigen-stimulated
T cells undergoing multiple divisions remained present.
However, when the dose was increased to 66 mg/kg, GVHD
was alleviated, and only the ﬁrst 2 to 3 generations of the
rapidly dividing alloreactive T cells remained. Cells undergoing more divisions did not survive, whereas slowly
dividing cells were also preserved. In a different study published in abstract form, Cieri et al. [22] studied immune
reconstitution during the ﬁrst month in a series of patients
undergoing T cellereplete peripheral blood haploidentical
transplantation. GVHD prophylaxis consisted of posttransplant cyclophosphamide combined with MMF and
sirolimus. Although proliferating alloreactive T lymphocytes
were abated, memory cells, including stem memory cells
(CD45RAþ, CD62þ, and CD95þ), were increased. The authors
postulated that the increase in stem cell memory cells was
due to differentiation from naïve T cells. These cells escaped
the cyclophosphamide purging effect because of their
delayed proliferation in comparison with the alloreactive
T cells.
Taken together, these ﬁndings suggest that cyclophosphamide can prevent GVHD without compromising timely
immune reconstitution. This selective action of cyclophosphamide on proliferating T cells has a number of practical
implications. The ﬁrst implication relates to its potential use
in combination with other immunosuppressive agents. For
instance, the concomitant use of drugs that induce T cell
anergy and may prevent cells from cycling might be theoretically counterproductive [13]. The addition of such drugs
must rather be delayed. Pan T cell antibodies, on the other
hand, might be synergistic and enhance the deletion of the
relevant T cell clones [13]. On the downside, the selective
action of cyclophosphamide allows memory T cells induced
by prior alloimmunization of the recipient to escape cyclophosphamide and increase the risk of graft failure.
Finally, the effect of cyclophosphamide on regulatory
T cells (Tregs) has been the subject of intense investigation.
Although early animal studies suggested a negative effect of
cyclophosphamide on Tregs, different results were obtained
in human studies. North [23] demonstrated that cyclophosphamide can facilitate adoptive immunotherapy of established tumors in mice. Although the administration of
cyclophosphamide failed to cause tumor regression, the
combination of cyclophosphamide and spleen cells permanently abolished the tumor. The authors postulated that
“suppressor but not immune T cells” were sensitive to
cyclophosphamide. Similarly, Ghiringhelli et al. [24]
demonstrated that the administration of a single dose of
cyclophosphamide to rats with established tumor depleted
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CD4þCD25þ cells and rendered the tumor sensitive to weak
immunotherapies. A study by Kanakry et al. [25] in humans
receiving myeloablative matched related-donor allogeneic
blood and marrow transplants yielded contrary results. That
study examined the effect of post-transplant cyclophosphamide on the different subsets of Tregs. The numbers of naïve
Tregs (CD4þCD45RAþFoxp3þlo) were lower in patients
compared with donors, possibly because of their conversion
to activated Tregs (CD4þCD45RAFoxp3þhi). Indeed, activated Tregs increased as did the total number of naïve and
activated cells. The authors also demonstrated that the
content of different Tregs in aldehyde dehydrogenase
increased upon activation by allogeneic stimuli, rendering
them resistant to mafosfamide. The cells were conversely
sensitized by aldehyde dehydrogenase inhibition. The same
group studied the role of Tregs in the cyclophosphamide
GVHD prophylactic effect. Using a xenogenic GVHD mouse
model, when peripheral blood mononuclear cell grafts were
depleted of Tregs, the mice had higher GVHD scores and died
earlier. These ﬁndings emphasize the requirement for Tregs
for the optimal effect of cyclophosphamide.
To summarize, Mayumi et al. and Luznik et al. [13,26]
proposed a 3-step scheme to explain the mechanism for
induction of tolerance by post-transplant cyclophosphamide. Early, proliferating alloreactive donor and recipient
T cells are selectively destroyed. Next, the increased Tregs
counterbalance the effect of any remaining alloreactive
mechanisms. Finally, the delayed but long-lasting intrathymic clonal deletion of anti-host T cells maintains longterm tolerance.
CLINICAL STUDIES
Haploidentical Transplant
Most early clinical studies on the use of post-transplant
cyclophosphamide for the prevention of GVHD were performed in the setting of haploidentical transplantation
(Table 1). O’Donnell et al. [27] at Johns Hopkins University in
Baltimore conducted a pivotal clinical trial that set the stage
for others. Patients with high-risk hematological malignancies received T cellereplete haploidentical bone marrow
grafts after nonmyeloablative conditioning with 150 mg/m2
ﬂudarabine on days 6 to 2 and 2-Gy total body irradiation
(TBI) on day 1 followed by 50 mg/kg cyclophosphamide on
day þ3 in combination with MMF from days þ4 to þ35 and
tacrolimus from day þ4 to at least day þ50. Two of the ﬁrst 3
patients developed graft rejection. Therefore, 14.5 mg/kg/day
of cyclophosphamide was added on days 6 and 5. Eight of
the 10 subsequent patients achieved sustained engraftment.
Overall, 6 of 13 patients (46%) developed acute GVHD at a
median of 99 days after transplant, with fatal acute GVHD in
1 patient. This study provided proof of principle that posttransplantation cyclophosphamide can be safely administered in the setting of haploidentical hematopoietic stem cell
transplantation, eliminating the need for T celledepleted
mega cell dose grafts [27].
Building on these ﬁndings, Luznik et al. [28] compared
the outcome of patients with advanced hematological malignancies receiving 1 (n ¼ 28) or 2 (n ¼ 40) doses of
cyclophosphamide administered on days þ3 or þ3 and þ4,
respectively, in addition to MMF and tacrolimus. All 68
patients underwent nonmyeloablative conditioning as
described above, followed by T cellereplete haploidentical
bone marrow grafts. Nine of 66 assessable patients (13%)
had graft failure. The remainder engrafted with a median
time to neutrophil recovery of 15 days and to platelet

recovery of 24 days. The cumulative incidence of treatmentrelated mortality (TRM) of the entire group was 15%,
whereas the relapse rate at 1 year was 51%. The 2-year
overall survival (OS) and event-free survival (EFS) rates
were 36 and 26%, respectively. Thirty-four percent of
patients developed acute GVHD grades II to IV and 6%
developed grades III to IV. The only difference between the
2 groups was a trend toward a lower incidence of extensive
chronic GVHD (5% versus 25%; P ¼ .05) for patients receiving
2 doses of cyclophosphamide. The robust suppression of
alloreactivity by post-transplant cyclophosphamide was
further supported by a retrospective analysis of 3 similar
trials that revealed the number of HLA mismatches at A, B,
C, and DRB1 loci had no impact on EFS and the incidence of
grades II to IV acute GVHD [29].
More recently, Munchel et al. [30] reported on behalf of
the Johns Hopkins University group the results of a large
phase II study enrolling 210 patient with advanced hematological malignancies. Patients received haploidentical bone
marrow transplants using the group’s original nonmyeloablative conditioning regimen and GVHD prophylaxis
protocol. Eighty-seven percent of patients experienced
sustained engraftment. The incidence of 5-year TRM was
18%. The incidence of disease relapse was 55%, with EFS and
OS rates of 35% and 27% respectively. The incidence of acute
grades II to IV GVHD and chronic GVHD was 27% and 13%,
respectively, conﬁrming the notably low incidence of chronic
GVHD.
The Bone Marrow Transplant Clinical Trials Network
sponsored a trial treating in parallel 2 groups of patients at
two different centers. The ﬁrst group received haploidentical
blood and marrow transplantation with post-transplant
cyclophosphamide, and the second group received umbilical cord blood transplant in patients with high-risk hematological malignancies [31]. The ﬁrst group received the same
nonmyeloablative conditioning regimen used by the Johns
Hopkins University group. The second group received a
conditioning regimen combining ﬂudarabine 160 mg/m2,
cyclophosphamide 50 mg/kg, and TBI 2 Gy. The OS and EFS
rates were 62% and 48%, respectively, for the haploidentical
transplants and 54% and 46%, respectively, for the group
receiving cord blood transplant. The incidence of acute GVHD
grades II to IV and III to IV was 32% and 0%, respectively, for
the ﬁrst group and 40% and 21%, respectively, for the second
group. The 1-year rate of chronic GVHD was 13% and 25%,
respectively. The authors concluded that both approaches
were useful and provided outcomes similar to the outcome
of patients receiving reduced-intensity conditioning transplants from matched related or matched unrelated donors.
This conclusion is consistent with Bashey et al.’s [32] retrospective analysis of 53 patients receiving haploidentical bone
marrow or peripheral blood stem cells with post-transplant
cyclophosphamide in comparison with patients treated at
the same center with matched related (n ¼ 117) or unrelated
(n ¼ 101) donor transplants receiving standard GVHD prophylaxis. This latter study also demonstrated no difference in
TRM, relapse, or survival rates, with a similar incidence of
GVHD.
Although most initial studies focused on the use of bone
marrow, several recent studies explored the role of posttransplant cyclophosphamide in permitting the use of peripheral blood instead of bone marrow and to omit the need
for mega cell dose grafts originally introduced to induce
immune tolerance [33]. Solomon et al. [34] studied 20
patients with hematological malignancies, 11 of whom had

Table 1
Summary of the Published Studies Using Post-Transplant Cyclophosphamide for Prophylaxis of GVHD
Type of Study

No. of
Median
Patients Patient
Age (yr)

27
O’Donnell

Prospective

13

28
Luznik

Prospective

68

29
Kasamon

Retrospective
from 3 trials
(67 patients were
included
in reference 23)
Prospective

Conditioning
Regimen

Graft Failure

GVHD Prophylaxis

HID-BM

Cy50  1 þ MMF þ TAC
4 (30%)
(2 of the ﬁrst
3 patients)
9 (14%)
Cy50  1 (28) or Cy50
 2 (40) þ MMF þ TAC

Acute GVHD
Median
Follow-Up Grades II-IV
(mo)

Chronic GVHD

TRM, EFS, OS

46%

NR

18%, 38%, 46%

24

34%

15%, 26%, 36%

6

31%

Cy50  1: 25%
Cy50  2: 5%
P ¼ .05
15%

27%

13%

6.4

HID-BM

185

50

JH

HID-BM

29 (16%)

Cy50  1 (48) or Cy50
 2 (137) þ MMF þ TAC

210

52

HID-BM

100

HID: 48
CB: 58

Of 204: 27
(13%)
HID: 1 (2%)
CB: 6 (12%)

Cy50  2 þ MMF þ TAC

Comparison of
2 separate
prospective
conducted in
parallel

Flu þ Cy þ TBI (2)
NMA
HID: JH
CB: Flu þ Cy þ TBI
(2 Gy)

HID: Cy50  2 þ
MMF þ TAC
CB: MMF þ CSA

12

HID: 32%
CB: 40%

32
Bashey

Retrospective
comparison
between 2
groups of patients

271

HID: 46
MRD: 50
MUD: 51

HID: JH (35) or Flu þ
Bu þ Cy (MA) (18)
MRD: MA (70) or
NMA (47)
MUD: MA (47) or
NMA (54)

HID: BM (32),
HID: PB(21)
MRD and MUD:
PB (most)

NR

HID: Cy50  2 þ
MMF þ TAC

24

HID: 30%
MRD: 27%
MUD: 39%

34
Solomon
35
Bhamidipati
Abstract

Prospective

20

44

Flu þ Bu þ Cy (MA)

HID-PB

0

Cy50  2 þ MMF þ TAC

20

30%

Retrospective

18

41

JH

HID-PB

2 (11%)

36
Ciurea

Retrospective
comparison
between 2 groups
of patients

65

TCR: 45
TCD: 36

TCR: MA (26) or
NMA (6)
TCD: MA

TCR: HID-BM (31)
HID-PB (1)
TCD: HID-PB

TCR 6%
TCD: 19%

Cy50  2 þ MMF þ
TAC (16)
Cy50  2 þ MTX þ
TAC (2)
TCR: Cy50  2 þ
MMF þ TAC
TCD: ATG

37
Castagna

Retrospective
comparison
between 2 groups
of patients

69

HID-BM: 44 JH
HID-PB: 54

HID-BM (46)
HID-PB (23)

Reported as
similar
between
the 2 groups

38
Gayoso
Abstract

Retrospective
review:
Hodgkin disease

29

31

NR

HID-BM (in 1 study)
CB (in the second
study)

HID-BM (15)
Flu þ Cy þ TBI 2
HID-PB (14)
(NMA) or
Flu þ Cy þ Bu (NMA)

8.4

40.7%

18%, 32% at 3 y,
41% at 3 yr
HID: 13%
HID: 7%, 48%
CB: 25%
at 1 y, 62% at 1 yr
CB: 24%, 46%
at 1 y, 54% at 1 yr
Relapse
HID: 45% CB: 31%
HID: 7%, 60% at
HID: 4%
2 y, 64% at 2 yr
MRD: 11%
MRD: 13%, 53%
MUD: 12%
P ¼ .05 in favor at 2 y, 76% at 2 yr
of HID vs. MRD MUD: 16%, 52% at
2 y, 67% at 2 yr
or MUD
*all were severe Relapse
HID: 33% MRD
and MUD: 34%
35%
10%, 50% at 1 yr, 69%
at 1 yr
8%
17%, 53% at 1 yr, 62%
at 1 yr

TCR: 11
TCD: 48

TCR: 20%
TCD: 11%

Cy50  2 þ MMF þ
CSA or TAC

18

HID-BM: 25% HID-BM: 13%
HID-PB: 33% HID-PB: 13%

Cy50  2 þ MMF þ
CSA or TAC

9

25%

15%, 35% at 1 yr, NR

TCR: 7%
TCD: 18%
P ¼ .03

16%

TCR: 16%, 50% at
1 yr, 64% at 1 yr
TCD: 42%, 21%
at 1 yr, 30% at 1 yr
P ¼ .02
2 y HID: BM 22%
PB 12%, reported as
similar between
2 groups (62%),
reported as similar
between 2 groups
(68%)
17% 59%, NR
Relapse 21%
(continued on next page)
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JH (ﬁrst 3 patients
without Cy on
days e6 and e5)
Range .5-70 JH

30
Munchel
31
Brunstein

53

Donor and
Graft Source
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Reference
First author

JH indicates Johns Hopkins University regimen; Cy, cyclophosphamide; HID, haploidentical donor; BM, bone marrow; MMF, mycophenolic acid; TAC, tacrolimus; NR, not reported; NMA, nonmyeloablative; CB, cord blood; Flu,
ﬂudarabine; CSA, cyclosporine A; MRD, matched related donor; MUD, matched unrelated donor; Bu, busulfan; MA, myeloablative; PB, peripheral blood; Mel, melphalan; MTX, methotrexate; ATG, antithymocyte globulin.

NR
0%
NR

14
39
Prospective:
Bolaños-Meade sickle cell
disease
40
Prospective
117
Luznik
Prospective
92
41
Kanakry
Abstract
74
Comparison of 2
42
matched groups
Alousi
of patients (Cy for
Abstract
GVHD prophylaxis
versus standard)
45
Case report:
2
Dezern
aplastic anemia

54.5

MRD-BM

Cy: Flu þ Bu (ATG
if MUD)
Control: Flu þ Bu or
Flu þ Mel (ATG
if MUD)
Cy þ Bu (MA)
Cy: 61
Control:62

0

Cy50  2 þ MMF þ TAC

0%

Cy: 36%, 22%, 26%
Control: 16%, 33%, 46%
P ¼ .08
CY: 14%
Control: 21%
NR

Flu þ Bu (MA)
NR

MRD or MUD-BM 26 NR
MRD or MUD-PB 11
in each group

Cy: Cy50  2
Control: MMF or
MTX þ TAC

CY: 46%
Control: 19%
P ¼ .02

14%
51%
19.2
Cy50  2

10%
43%
26.3
Cy50  2

MRD-BM (78)
MUD-BM (39)
MRD-BM (45)
MUD-BM (47)
Bu þ Cy (MA)
50

MRD: 1 (1%)
MUD: 2 (5%)
NR

0%
0%
23.7
Cy50  2 þ MMF þ
CSA or TAC
HID-BM
Flu þ Cy þ TBI
(2 Gy) þ ATG
23.5

6 (43%)

Chronic GVHD
Acute GVHD
Median
Follow-Up Grades II-IV
(mo)
GVHD Prophylaxis
Graft Failure
Donor and
Graft Source
Conditioning
Regimen
No. of
Median
Patients Patient
Age (yr)
Type of Study
Reference
First author

Table 1
(continued )

0%, 57% abatement
of sickle cell crisis,
100%
17%, 39% at 2 yr, 55%
at 2 yr
16%, 62% at 2 yr, 67%
at 2 yr
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TRM, EFS, OS
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relapsed disease. Patients received a busulfan-based myeloablative conditioning regimen followed by T cellereplete
peripheral blood stem cells from haploidentical donors. The
maximal CD34 cell dose was 5  106/kg. GVHD prophylaxis
consisted of cyclophosphamide 50 mg/kg on days þ3
and þ4 followed by tacrolimus and MMF starting on day þ5.
All patients engrafted. One-year OS and EFS rates were 69%
and 50%, respectively, for the entire group and 88% and 67%
for the 9 patients in remission at the time of transplant. The
overall incidences of grades II to IV and grades III to IV acute
GVHD were 30% and 10%, respectively. At a median followup of 20 months, the incidence of chronic GVHD was 35%
(5% severe). These results were substantiated by Bhamidipati et al. [35] for nonmyeloablative conditioning. The
incidence of extensive chronic GVHD in this study was also
5%.
Furthermore, 2 additional studies reported the results of
retrospective comparisons between haploidentical transplants using bone marrow or peripheral blood as the source
of grafts. First, Ciurea et al. [36] analyzed 65 consecutive
patients with hematological malignancies receiving
T cellereplete peripheral blood stem cell transplants (n ¼ 32,
TCR group) as opposed to T celledeplete bone marrow
transplants (n ¼ 33, TCD group). Both groups received the
same conditioning regimen combining ﬂudarabine,
melphalan, and thiotepa. The ﬁrst group was administered
post-transplant cyclophosphamide along with tacrolimus
and MMF for GVHD prophylaxis. For the TCD group, the only
GVHD prophylaxis consisted of 6 mg/kg rabbit antithymocyte globulin. There was no difference in engraftment between the 2 groups. However, TRM was lower in the TCR
group (16% versus 42%; P ¼ .02). OS and EFS rates were 64%
versus 30% (P ¼ .02) and 50% versus 21% (P ¼ .02), respectively, in favor of the TCR group. There was no signiﬁcant
difference in the incidence of acute GVHD grades II to IV (20%
in the TCR versus 11% in the TCD group; P ¼ .2), whereas
chronic GVHD was less frequent in the TRC group (7% versus
18%; P ¼ .03). Recovery of CD4þ and CD8þ cells was signiﬁcantly faster in the TCR transplant patients. This was also true
for naïve and memory T cells and translated into a lower
incidence of viral and fungal infections. The authors
concluded that the outcome of TCR transplants with posttransplant cyclophosphamide was superior to that of TCD
transplants. In the second study, Castagna et al. [37]
compared 2 groups receiving T cellereplete grafts. The ﬁrst
group received bone marrow grafts (n ¼ 46), whereas the
second group received peripheral blood grafts (n ¼ 23). No
differences in OS or EFS were observed. The incidences of
acute and chronic GVHD were also statistically similar.
Enrolling only patients with relapsed or refractory
Hodgkin disease, Gayoso et al. [38] presented the outcome of
29 patients conditioned with a combination of ﬂudarabine,
cyclophosphamide, and either busulfan (6.4 mg/kg) or TBI
2 Gy. Most patients (72%) had active disease at the time of
transplant. With a short follow-up, 59% of patients were in
complete remission. The rates of acute and chronic GVHD
were comparable with those reported in other studies.
Finally, the John Hopkins University group reported the
outcome of haploidentical transplantation in nonmalignant
illnesses using their original regimen [39]. Most patients in
this study had sickle cell disease. Six of 14 patients (43%) had
graft failure. The incidence of acute and chronic GVHD was
very low, with only 1 patient developing skin GVHD but
requiring no therapy. However, the low incidence of GVHD
might be due in part to the high rate of graft failure. At a
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Table 2
Summary of Selected Registered Trials Including Post-Transplant Cyclophosphamide for GVHD Prevention
Study Identiﬁcation

Study Type

Intervention

Responsible Party

NCT01749111

Phase III randomized

NCT01860170

Phase I

NCT01349101

Phase II

NCT02065154

Phase II

NCT00622895

Phase I/II

PTCy versus MTX and CNI for GVHD prevention in
MRD and MUD transplants
PTCy and bortezomib for GVHD prevention in MRD
and MUD transplants
PTCy, MMF, and tacrolimus for GVHD
prevention in haploidentical and MUD transplants
PTCy for GVHD prevention in MUD and mismatched
UD transplants
PYCy, MMF, and tacrolimus for GVHD
prevention in MRD and MUD transplants in severe
systemic sclerosis
PTCy for GVHD prevention in haploidentical and
MRD transplants for sickle cell disease.
Alloimmunized patients receive rituximab and
bortezomib with or without plasma exchange.
Patients receive donor lymphocyte infusion
followed by PTCy followed by CD34 selected graft.
PTCy, MMF, and tacrolimus for GVHD
prevention in haploidentical transplants using
peripheral blood
PTCy, MMF, and tacrolimus for GVHD prevention in
haploidentical transplants
PTCy, MMF, and tacrolimus for GVHD
prevention in haploidentical transplants using
peripheral blood
PTCy, MMF, and tacrolimus for GVHD
prevention in haploidentical transplants
PTCy for GVHD prevention in transplants for adult
ALL

Paulo V. Campregher, MD
Hospital Israelita Albert Einstein
A. Samer Al-Homsi, MD
Spectrum Health Hospitals
John L. Wagner, MD
Thomas Jefferson University
Racquel Innis-Shelton, MD
University of Alabama at Birmingham
George Georges, MD
Fred Hutchinson Cancer Research Center

NCT01350232

NCT02167958

Phase I

NCT01374841

Phase II

NCT01028716

Phase II

NCT02053545

Phase I/II

NCT01435447

Phase II

NCT01707004

Phase II

NCT02049580

Phase II

NCT02208037

Phase II randomized

NCT01719341

Phase II

NCT02169791

Phase II

PTCy, MMF, and tacrolimus for GVHD
prevention in haploidentical transplants
PTCy for prevention of GVHD in MRD and MUD
transplants for poor-risk lymphoma
PTCy, MMF, and tacrolimus, MTX,
tacrolimus, and bortezomib, or MTX, tacrolimus,
and maraviroc for prevention of GVHD in MRD,
MUD, and mismatched UD transplants

PTCy for GVHD prevention in haploidentical
transplants
PTCy, tacrolimus, and ixazomib for GVHD
prevention in haploidentical transplants.

Joanne Flilicko-O’Hara, MD
Thomas Jefferson University

Raﬁc Farah, MD
University of Pittsburgh
Rocco Pastano, MD
European Institute of Oncology
Rachel Salit, MD
Fred Hutchinson Cancer Research Center
Reggie E. Duerst, MD
Children’s Hospital of Chicago
Jiong Hu, MD
Shanghai Jiao Tong University School
of Medicine
Mark Juckett, MD
University of Wisconsin, Madison
Luca Castgna, MD
Istituto Clinico Humanitas
Javier Bolaños-Meade, MD
Johns Hopkins University
John Koreth, MBBS
Dana-Farber Cancer Institute
Ran Reshef, MD
University of Pennsylvania
Zi Yi Lim, MB ChB
National University Hospital, Singapore
Scot Solomon, MD
Northside Hospital

PTCy indicates post-transplant cyclophosphamide; CNI, calcineurin inhibitor; UD, unrelated donor; ALL, acute lymphoblastic leukemia.

median follow-up of almost 2 years, 11 patients were
asymptomatic and 6 were no longer on immunosuppressive
therapy. The high rate of graft failure in hemoglobinopathies
is not unique to this study. This can be explained by the lack
of prior cytotoxic chemotherapy or decreased sensitivity to
cyclophosphamide of effector T cells induced by alloimmunization secondary to multiple transfusions. The authors also
speculated that ABO incompatibility may be a factor [39].
Intensifying the degree of immunosuppression of the conditioning regimen and performing transplantation earlier in
the course of disease before alloimmunization occurs can
conceivably overcome these barriers.
Matched Related and Unrelated Transplant
Having established the role of post-transplant cyclophosphamide in the setting of haploidentical transplantation, the Johns Hopkins University group examined its
role in matched related and unrelated transplants as the only
GVHD prophylactic therapy. After performing a pilot study,
Luznik et al. [40] reported the results of a large cohort of
patients with advanced hematological malignancies who
received myeloablative conditioning followed by grafts from

matched related (n ¼ 78) or unrelated (n ¼ 39) donors.
Overall, TRM was 17%. OS and EFS rates at 2 years were 55%
and 39%, respectively, for the entire group and 63% and 54%,
respectively, for patients with no evidence of disease at the
time of transplantation. Acute GVHD grades II to IV occurred
in 43% of patients. The incidence of chronic GVHD was again
low at 10%.
Kanakry et al. [41] performed a similar multi-institutional
study using a combination of ﬂudarabine and busulfan at
myeloablative doses as the conditioning regimen. The source
of the grafts was T cellereplete bone marrow from matched
related (n ¼ 45) or unrelated (n ¼ 47) donors. Twenty-ﬁve
patients had active hematological malignancy at the time
of transplantation. Cyclophosphamide was the sole GVHD
prophylaxis. With a median follow-up of 1.6 years, the TRM
was 16%, and OS and EFS rates were 62% and 67%, respectively. The incidence of grades II to IV and III to IV acute GVHD
was 51% and 15%, respectively, whereas the incidence of
chronic GVHD was again low at 14%.
Finally, a matched controlled analysis of 2 groups
receiving either post-transplant cyclophosphamide or
tacrolimus and methotrexate as GVHD prophylaxis after
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matched related and unrelated donor reduced-intensity
transplants was reported in an abstract [42]. The TRM was
36% and 16% (P ¼ .1), respectively; progression-free survival
was 22% and 33% (P ¼ .4), respectively; and OS was 26% and
46% (P ¼ .08), respectively. The incidence of acute GVHD
grades II to IV was 46% and 19% (P ¼ .02), respectively, and
that of chronic GVHD was 14% and 21% (P ¼ .7), respectively.
The unfavorable outcomes of patients receiving posttransplant cyclophosphamide can be explained by the
surprisingly high TRM. In addition, the incidence of acute
GVHD in the control group was lower than traditionally
encountered.
ONGOING AND FUTURE CLINICAL TRIALS
A number of trials have been initiated to conﬁrm the
current data and also to compare haploidentical transplant
made practical by post-transplant cyclophosphamide with
matched sibling, matched unrelated, and cord blood
transplants. Conﬁrmatory studies examining the role
of cyclophosphamide are also underway in matched
related and unrelated donor transplants. In this setting,
cyclophosphamide is an appealing platform to be used in
combination with other agents. The options include combinations with calcineurin and m-TOR inhibitors or with pan
T cell antibodies. Other combinations using agents that affect
other cellular components involved in GVHD pathogenesis,
such as dendritic cells or cytokines, are attractive. The combinations with ruxolitinib, a potent suppressor of dendritic
cells and cytokines [43], or vorinostat, which possesses
anti-GVHD activity, also merit examination [44]. Table 2
summarizes selected registered clinical trials using cyclophosphamide for prevention of GVHD (other trials can be
found at clinicaltrials.gov).
CONCLUSION
Cyclophosphamide has a unique mechanism of action. It
selectively destroys rapidly proliferating donor- and hostalloreactive CD4þ cells while sparing slowly proliferating
cells. This is followed by clonal deletion of immature donor
CD4þ and CD8þ cells in the chimeric thymus. Subsequently,
although the preservation of naïve and activated Tregs
further sustains its immunosuppressive effect, the selective
nature of cyclophosphamide activity permits rapid immune
reconstitution and conceivably preserves the GVD effect. In
haploidentical settings, cyclophosphamide allows the use of
unmanipulated peripheral blood grafts, omitting the need
for any special expertise. In matched related and unrelated
donor transplants, cyclophosphamide alone is active, with a
notably low incidence of chronic GVHD. Conﬁrmatory and
comparative studies are warranted to examine the effect of
such approach on disease relapse and immune reconstitution. Post-transplant cyclophosphamide also offers the
opportunity to explore its use in conjunction with other
agents in innovative approach.
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